5 results about "Sphingolipid metabolism" patented technology

The invention relates to the technical field of drugs for treating hypertrophic scars, in particular to application of triglycosyl ceramide in treatment of hypertrophic scars. Based on a newly found molecular regulation mechanism, the heterogeneity of skin fibroblasts is regulated in a targeted manner, so that pathological fibrosis and scar formation in a burn wound healing process are effectively inhibited. The invention provides a strategy for accurately intervening the transdifferentiation of fibroblasts to myofibroblasts and promoting the fibrosis direction. In the prior art, an effective target spot aiming at a fibroblast heterogeneity key regulation and control node on a burn wound surface is lacked. The invention discloses a new'HEXB-Gb3-FGF2 'regulation axis, and develops a treatment method for specifically targeting a key product triglycosyl ceramide of glycosphingolipid metabolism.

The application of ceramide in the control of rice blast fungus falls within the field of biological control. This invention relates to the application of ceramide in the control of rice blast fungus: a combination of ceramide and lipopeptides is used for the control of rice blast fungus. Exogenous addition of ceramide significantly enhances the stress effect of lipopeptides on rice blast fungus. It also enhances the abnormal accumulation of glycogen and lipid droplets in conidia, promotes the bursting of ROS, and increases intracellular ceramide and calcium... 2+ The invention increases the content of malondialdehyde (MDA) in mycelium, enhances membrane lipid peroxidation, and decreases ergosterol content. Furthermore, it inhibits the expression of ergosterol synthesis genes, UPR target genes, and sphingolipid metabolism-related genes. This invention develops a highly efficient natural agent against rice blast by combining exogenous Cer with lipopeptides. This agent effectively reduces the pathogenicity of rice blast fungus and significantly inhibits its infection of rice, laying the foundation for the development of novel biological control agents.

The present disclosure pertains to the use of an Anc80 viral vector that encodes a sphingolipid-metabolizing protein such as acid ceramidase to achieve expression of the sphingolipid-metabolizing protein in a mammalian cell or group of cells. Expression of the protein from the Anc80 vector reduces high levels of ceramide in the cell that lead to cell death or senescence.

The invention provides a pharmaceutical composition and application thereof, and belongs to the technical field of biological medicine. The sphingolipid metabolite is added in the immune cell in-vitro culture process, the immune cell function is remodeled in a metabolic regulation mode, and the dryness and tumor killing capacity of the immune cells are remarkably enhanced.

The invention belongs to the technical field of medical biology, and particularly relates to an ALS mouse model constructed based on Sptlc-E260K point mutation and a construction method and application of the ALS mouse model. According to the Sptlc2-E260K point mutation mouse, key enzyme SPTLC2 is synthesized through targeted sphingolipid, functional mutation E260K is directly introduced, a sphingolipid metabolism pathway is abnormal, and the core pathology of sphingolipid metabolism imbalance in children type ALS is accurately simulated. Compared with SOD1 and TDP43 models, the invention fills up the blank of the existing model in the study of ALS related to sphingolipid metabolism, and provides a specific tool for exploring a neurodegenerative mechanism driven by abnormal metabolism. The method has the advantages that efficient identification is realized through selection of SPTLC2 gene targets and introduction of codon replacement and restriction enzyme cutting sites, so that the problem of incomplete pathological coverage caused by limitation of gene functions in the prior art is solved.